Cochrane · systematic review · CD004161
Risperidone (depot) for schizophrenia
Sampson, S, Hosalli, P, Furtado, VA, et al. · Cochrane Database of Systematic Reviews · 2016 · Cochrane Library
SchizophreniaAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
51
current version
GRADE rated
38
No studies
3
Included studies
NR
No studies 3 · 5.9%Ungraded 10 · 19.6%Very low 11 · 21.6%Low 17 · 33.3%Moderate 10 · 19.6%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
RISPERIDONE DEPOT compared with PLACEBO for schizophrenia
Population: patients with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Global state: Relapse ‐ long term ‐ not measured RISPERIDONE DEPOT vs PLACEBO | no estimate extracted | NR | No studies |
Mental state: clinically significant improvement in mental state ‐ long term1 ‐ not reported RISPERIDONE DEPOT vs PLACEBO | no estimate extracted | NR | No studies |
Leaving the study early: Any reason ‐ all doses risperidone depot ‐ short term RISPERIDONE DEPOT vs PLACEBO | RR 0.74 [0.63, 0.88] | 1 study · 400 participants | Very low Downgraded: risk of bias, imprecision |
Adverse events: General: Severe adverse event ‐ any dose risperidone depot ‐ short term Spontaneous reporting by study participants RISPERIDONE DEPOT vs PLACEBO | RR 0.59 [0.38, 0.93] | 1 study · 400 participants | Very low Downgraded: risk of bias, imprecision |
Adverse events: Specific: Weight gain ‐ all doses of depot risperidone ‐ short term Spontaneous reporting by study participants RISPERIDONE DEPOT vs PLACEBO | RR 2.11 [0.48, 9.18] | 1 study · 400 participants | Very low Downgraded: risk of bias, imprecision |
RISPERIDONE DEPOT compared with GENERAL ORAL ANTIPSYCHOTICS for schizophrenia
Population: patients with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Global state: Relapse (any reason) ‐ long term Number of participants relapsing in each treatment arm. RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS | RR 2.13 [0.84, 5.43] | 1 study · 63 participants | Very low Downgraded: risk of bias, imprecision |
Mental state: clinically significant improvement in mental state ‐ long term RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS | no estimate extracted | 0 studies · 0 participants | Ungraded |
Leaving the study early: Any reason ‐ long term RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS | RR 1.24 [0.98, 1.57] | 2 studies · 467 participants | Moderate Downgraded: risk of bias, imprecision |
Adverse events: General: Severe adverse event ‐ any dose risperidone depot ‐ short term RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS | no estimate extracted | 0 studies · 0 participants | Ungraded |
Adverse events: Specific ‐ prolactin‐related ‐ long term It is unclear how adverse events were reported RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS | RR 10.27 [0.59, 180.05] | 1 study · 85 participants | Very low Downgraded: risk of bias, imprecision |
Adverse events: Specific ‐ weight increase ‐ long term It is unclear how adverse events were reported RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS | RR 1.33 [0.56, 3.17] | 1 study · 85 participants | Very low Downgraded: risk of bias, imprecision |
Adverse events: Nervous system disorders (inc. EPS) ‐ long term It is unclear how adverse events were reported RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS | RR 1.34 [1.13, 1.58] | 1 study · 369 participants | Very low Downgraded: risk of bias, imprecision |
RISPERIDONE DEPOT compared with ORAL RISPERIDONE for schizophrenia
Population: patients with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Global state: Relapse ‐ long term RISPERIDONE DEPOT vs ORAL RISPERIDONE | no estimate extracted | 0 studies · 0 participants | Ungraded |
Mental state: average PANSS total score at endpoint (non‐ITT data) PANSS total scores (30 to 210) Higher scores are worse. RISPERIDONE DEPOT vs ORAL RISPERIDONE | no estimate extracted | 2 studies · 591 participants | Moderate Downgraded: risk of bias |
Leaving the study early: Any reason ‐ short term RISPERIDONE DEPOT vs ORAL RISPERIDONE | RR 1.28 [0.92, 1.79] | 2 studies · 690 participants | Moderate Downgraded: risk of bias |
Adverse events: General: Severe adverse event ‐ any dose risperidone depot ‐ short term RISPERIDONE DEPOT vs ORAL RISPERIDONE | no estimate extracted | 0 studies · 0 participants | Ungraded |
Adverse events: Movement disorder ‐ any extra pyramidal symptoms ‐ short term RISPERIDONE DEPOT vs ORAL RISPERIDONE | RR 1.05 [0.59, 1.88] | 1 study · 640 participants | Moderate Downgraded: risk of bias |
Adverse events: Specific: Mean (SD) weight increase in kg ‐ short term RISPERIDONE DEPOT vs ORAL RISPERIDONE | no estimate extracted | 1 study · 640 participants | Moderate Downgraded: risk of bias |
Adverse events: Specific ‐ prolactin‐related RISPERIDONE DEPOT vs ORAL RISPERIDONE | RR 0.5 [0.15, 1.65] | 1 study · 640 participants | Moderate Downgraded: risk of bias |
RISPERIDONE DEPOT compared with ORAL QUETIAPINE for schizophrenia
Population: patients with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Global state: Relapse ‐ long term RISPERIDONE DEPOT vs ORAL QUETIAPINE | no estimate extracted | 0 studies · 0 participants | Ungraded |
Mental state: clinically significant improvement in mental state ‐ long term RISPERIDONE DEPOT vs ORAL QUETIAPINE | no estimate extracted | 0 studies · 0 participants | Ungraded |
Leaving the study early: Any reason ‐ long term RISPERIDONE DEPOT vs ORAL QUETIAPINE | RR 0.84 [0.74, 0.95] | 1 study · 666 participants | Moderate Downgraded: risk of bias |
Adverse events: General ‐ serious Recorded at each RISPERIDONE DEPOT vs ORAL QUETIAPINE | RR 0.84 [0.62, 1.13] | 1 study · 666 participants | Low Downgraded: risk of bias |
Adverse events: Movement disorder ‐ any extra pyramidal symptom RISPERIDONE DEPOT vs ORAL QUETIAPINE | RR 1.83 [1.07, 3.15] | 1 study · 666 participants | Low Downgraded: risk of bias |
Adverse events: Specific: Mean (SD) weight increase in kg ‐ long term RISPERIDONE DEPOT vs ORAL QUETIAPINE | no estimate extracted | 1 study · 666 participants | Low Downgraded: risk of bias |
Adverse events: Specific ‐ prolactin‐related Reported by participants at RISPERIDONE DEPOT vs ORAL QUETIAPINE | RR 3.07 [1.13, 8.36] | 1 study · 666 participants | Low Downgraded: risk of bias |
RISPERIDONE DEPOT compared with ORAL ARIPIPRAZOLE for schizophrenia
Population: patients with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Global state: Relapse (any reason) ‐ long term Assessed by 5 blinded raters in accordance with study criteria (see comment). RISPERIDONE DEPOT vs ORAL ARIPIPRAZOLE | RR 1.05 [0.83, 1.33] | 1 study · 349 participants | Low Downgraded: risk of bias |
Mental state: Average change scores‐ long term PANSS total score (30 to 210), higher scores are worse. RISPERIDONE DEPOT vs ORAL ARIPIPRAZOLE | no estimate extracted | 1 study · 349 participants | Low Downgraded: risk of bias |
Leaving the study early: Any reason ‐ long term RISPERIDONE DEPOT vs ORAL ARIPIPRAZOLE | RR 0.83 [0.53, 1.3] | 2 studies · 723 participants | Very low Downgraded: risk of bias, imprecision |
Adverse events: General ‐ serious Unclear how these events were reported RISPERIDONE DEPOT vs ORAL ARIPIPRAZOLE | RR 0.96 [0.66, 1.39] | 2 studies · 729 participants | Very low Downgraded: risk of bias, imprecision |
Adverse events: Movement disorder ‐ any extra pyramidal symptoms RISPERIDONE DEPOT vs ORAL ARIPIPRAZOLE | RR 1.19 [0.91, 1.55] | 2 studies · 729 participants | Very low Downgraded: risk of bias, imprecision |
Adverse events: Specific ‐ weight increase RISPERIDONE DEPOT vs ORAL ARIPIPRAZOLE | RR 1.57 [0.38, 6.45] | 1 study · 374 participants | Low Downgraded: risk of bias |
Adverse events: Specific ‐ prolactin‐related RISPERIDONE DEPOT vs ORAL ARIPIPRAZOLE | RR 9.91 [2.78, 35.29] | 2 studies · 729 participants | Very low Downgraded: risk of bias, imprecision |
RISPERIDONE DEPOT compared with ORAL OLANZAPINE for schizophrenia
Population: patients with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Global state: Relapse ‐ long term RISPERIDONE DEPOT vs ORAL OLANZAPINE | no estimate extracted | 0 studies · 0 participants | Ungraded |
Mental state: Average change scores ‐ long term PANSS total score (30‐210), high scores are worse. RISPERIDONE DEPOT vs ORAL OLANZAPINE | no estimate extracted | 1 study · 361 participants | Low Downgraded: risk of bias |
Leaving the study early: Any reason ‐ long term RISPERIDONE DEPOT vs ORAL OLANZAPINE | RR 1.32 [1.1, 1.58] | 1 study · 618 participants | Low Downgraded: risk of bias |
Adverse events: General ‐ serious RISPERIDONE DEPOT vs ORAL OLANZAPINE | RR 1.1 [0.8, 1.51] | 1 study · 547 participants | Low Downgraded: risk of bias |
Adverse events: Movement disorder ‐ any extra pyramidal symptoms RISPERIDONE DEPOT vs ORAL OLANZAPINE | RR 1.67 [1.19, 2.36] | 1 study · 547 participants | Low Downgraded: risk of bias |
Adverse events: Specific ‐ weight increase RISPERIDONE DEPOT vs ORAL OLANZAPINE | RR 0.56 [0.42, 0.75] | 1 study · 547 participants | Low Downgraded: risk of bias |
RISPERIDONE DEPOT compared with ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE) for schizophrenia
Population: patients with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Global state: Relapse ‐ long term RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE) | no estimate extracted | 0 studies · 0 participants | Ungraded |
Mental state: PANSS responders (ITT data) ‐ medium term PANSS responders‐ participants achieving a >30% improvement in total score RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE) | RR 1.01 [0.83, 1.23] | 2 studies · 1326 participants | Moderate Downgraded: risk of bias |
Leaving the study early: lack of efficacy ‐ long term RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE) | RR 0.6 [0.45, 0.81] | 1 study · 749 participants | Low Downgraded: risk of bias |
Adverse events: Movement disorder requiring the use of anti‐EPS medication ‐ medium term RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE) | RR 1.46 [1.18, 1.8] | 2 studies · 1666 participants | Moderate Downgraded: risk of bias, imprecision |
Adverse events: Body weight (mean increase) ‐ medium/long term RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE) | no estimate extracted | 3 studies · 2350 participants | Low Downgraded: risk of bias |
Adverse events: Any prolactin‐related ‐ medium term RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE) | RR 1.02 [0.61, 1.71] | 2 studies · 1666 participants | Moderate Downgraded: risk of bias |
Adverse events: Any glucose‐related ‐ medium/long term RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE) | RR 1.79 [0.89, 3.61] | 3 studies · 2413 participants | Low Downgraded: risk of bias |
RISPERIDONE DEPOT compared with TYPICAL DEPOT ANTIPSYCHOTICS for schizophrenia
Population: patients with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Global state: Relapse ‐ long term RISPERIDONE DEPOT vs TYPICAL DEPOT ANTIPSYCHOTICS | no estimate extracted | 0 studies · 0 participants | Ungraded |
Mental state: Total average scores (PANSS, high score = worse) ‐ long term RISPERIDONE DEPOT vs TYPICAL DEPOT ANTIPSYCHOTICS | no estimate extracted | 1 study · 43 participants | Low Downgraded: risk of bias, imprecision |
Leaving the study early for any reason ‐ long term RISPERIDONE DEPOT vs TYPICAL DEPOT ANTIPSYCHOTICS | RR 3.05 [1.12, 8.31] | 1 study · 62 participants | Low Downgraded: risk of bias, imprecision |
Adverse events: General: Severe adverse event RISPERIDONE DEPOT vs TYPICAL DEPOT ANTIPSYCHOTICS | no estimate extracted | 0 studies · 0 participants | Ungraded |
Adverse events: related to movement disorder, weight gain, prolactin levels and glucose metabolism ‐ medium/long term ‐ not reported RISPERIDONE DEPOT vs TYPICAL DEPOT ANTIPSYCHOTICS | no estimate extracted | NR | No studies |